Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Citado por Google
- Similares em SciELO
- Similares em Google
Compartilhar
Revista Colombiana de Reumatología
versão impressa ISSN 0121-8123
Resumo
MUNOZ-GRAJALES, Carolina; MUNOZ VAHOS, Carlos Horacio; DIAZ BETANCUR, James e RAMIREZ GOMEZ, Luis Alberto. Frequency of anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatic diseases from a rheumatology outpatient center in Medellin, Colombia. Rev.Colomb.Reumatol. [online]. 2014, vol.21, n.4, pp.177-182. ISSN 0121-8123. https://doi.org/10.1016/j.rcreu.2014.10.001.
Introduction: The initiation of therapy in rheumatoid arthritis prevents joint damage, but this requires an early diagnosis. The detection of rheumatoid factor and anti-cyclic citrullinated peptide is part of the initial diagnostic approach of patients with arthritis. Objective: To determine the frequency of rheumatoid factor and anti-cyclic citrullinated peptide in patients with rheumatoid arthritis and other rheumatic diseases in patients of a rheumatology outpatient center in Medellin, Colombia. Methods: An evaluation is made of the presence of rheumatoid factor and anti-cyclic citrullinated peptide in 246 subjects (64 with rheumatoid arthritis, 80 with other rheumatic diseases, 61 with osteoarthritis and 41 healthy or with fibromyalgia). Results: In rheumatoid arthritis patients the frequency of rheumatoid factor, anti-cyclic citrullinated peptide, and double positivity (rheumatoid factor and anti-cyclic citrullinated peptide simultaneously) was: 86%, 83% and 80%, respectively, and in other rheumatologic diseases it was: 12.5%, 6%, and 1%, respectively. No subjects with fibromyalgia, or healthy, tested positive for anti-cyclic citrullinated peptide, but up to 5% showed positivity for rheumatoid factor. Conclusion: The possibility of positivity for rheumatoid factor and anti-cyclic citrullinated peptides in diseases other than rheumatoid arthritis and in healthy people should be taken into account, and particularly rheumatoid factor.
Palavras-chave : Rheumatoid factor; Rheumatoid arthritis; Anti-cyclic citrullinated peptide antibodies; Arthritis; Diagnosis.